ERBB2 and breast cancer: Patricia et al. confirmed that after neoadjuvant therapy, the patient can achieve better event-free survival (EFS) and overall survival (OS) in the pathological complete response (pCR), especially in triple-negative breast cancer (EFS: HR0.24; OS: 0.16) and HR-negative HER2-positive breast cancer (EFS: 0.15; OS: 0.08) [1].